Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn
Pharmaceutical giant Astrazeneca with CEO Pascal Soriot wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its...
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Under the terms of a new licencing and co-development deal, Boehringer Ingelheim will receive the exclusive, worldwide rights from Kyowa Kirin to...
Obesity: Arecor Therapeutics partners with TRx Biosciences
The collaboration of the biopharma and drug discovery specialists targets a potential US$80bn market of obesity drugs, according to Bloomberg...
Cambridge university spin-out HutanBio Ltd bags £2.25m seed financing
HutanBio, a Malaysian spin-out from scientists at Cambridge University, UK, has bagged a first tranche of seed investment from London-based Clean...
Alfasigma SpA signs €170m deal with Galapagos NV
With the transaction that is expected to close in Q1/2024, Alfasigma will strengthen its pipeline, add a new Phase III programme to...
Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...